


22 November 2007

ASX / MEDIA RELEASE



Leading lymphoedema text recognises bioimpedance technology

ImpediMed Limited (ASX:IPD) announced today that the value of bioimpedance technology for the early detection of lymphoedema has been recognised in the latest edition of "Lymphedema Diagnosis and Therapy"* Known to clinicians as the 'green book', it is a highly respected standard reference work on lymphology for physicians and lymph drainage therapists.

In this fourth edition, every chapter has been updated to reflect the latest findings in anatomy, diagnostics and treatment. The fourth English edition is a further update and enlargement of its German counterpart and contains an additional chapter on bioimpedance.

ImpediMed CEO, Greg Brown said it was encouraging to see an important clinical reference such as the 'green book' acknowledging the importance of bioimpedance to the identification and management of lymphoedema.

"Bioimpedance spectroscopy and single low frequency bioimpedance can make an important contribution to the early identification of the presence of lymphoedema, allowing the clinician to commence effective treatment at the earliest opportunity."

ImpediMed's bioimpedance technology is used in the only FDA-cleared device available for clinical assessment of secondary lymphoedema in the arm.

For more information contact:

Greg Brown
John Lamont

ImpediMed Limited - CEO
Phillips Group – Media Relations

Office: +61-7-3423-1777
Mobile: +61-408-737-450

ENDS

• **About ImpediMed Limited:**

ImpediMed Limited was incorporated in 1999 by The University of Queensland's main technology commercialisation company, UniQuest Pty Ltd. The Brisbane-based company began operations in 2000 to commercialise technology developed by researchers from the University of Queensland and the Queensland University of Technology.

ImpediMed Limited develops and globally markets medical device systems for use in non-invasive screening and monitoring of human disorders and diseases.

ImpediMed's primary product range consists of a number of medical devices that enable the early detection and monitoring of secondary lymphoedema in cancer survivors before the onset of symptoms that are detectable using the most commonly used clinical technique.

ImpediMed has the only medical device with an FDA clearance in the United States for the clinical assessment by Health Care Providers of secondary lymphoedema in the arm. This device is targeted to be launched internationally before the end of the year.

www.impedimed.com

* 4th ed."by H. Weissleder and C. Schuchhardt (eds.) November 2007 Viavital Verlag GmbH

For personal use only